I've now had a quick look at the full paper, and I think that confirms my view that 'the jury is out' (particularly for people like yourself).
Perhaps the most important thing to note is that the entire study (looking at some 28k patients in 7 published studies) relates to patients with "established coronary arty disease" (i.e. those who had suffered heart attacks or were suffering from angina) who took either aspirin or clopidogrel primarily to reduce the risk of further cardiac events. I'm not aware of your being such a person, and the study cannot necessarily be taken to mean anything in relation to people without "established coronary artery disease" and who are taking aspirin or clopidogrel for non-cardiac reasons.
In terms of results for individual (not 'muddled together') outcomes/events (in the population described above):
1... The only highly 'statistically significant' ("p=0.0003") difference between aspirin and clopidogrel was in relation to myocardial infarction (heart attacks).
2... Strokes as a whole were somewhat less common with clopidogrel than with aspirin, and this was just 'statistically significant' ("p=0.03"). However "ischaemic (thrombotic or embolic) strokes" (the only type of strokes that aspirin or clopidogrel would be expected to reduce) did not show a statistically significant difference ("p=0.09") - a significant difference only being seen when haemorrhagic strokes (which aspirin & clopidogrel could not prevent, and might even increase the risk of) were lumped together with the ischaemic ones"
3... Deaths from any cause, and cardiovascular deaths, were almost identical with the two drugs.
4... In terms of unwanted ("side") effects, "any bleeding", "major bleeding", "any gastrointestinal bleeding" and "major gastrointestinal bleeding" all failed to show any appreciable or significant difference between the two drugs.
So, in patients with established coronary artery disease, patients taking clopidogrel suffered significantly less heart attacks than those taking aspirin, although cardiovascular death was not significantly reduced. Strokes as a whole were somewhat (but 'significantly') less common in patients taking clopidogrel but since this was not the case in relation to ischaemic strokes, this finding probably needs to be regarded with caution. There seemed to be no appreciable difference between the drugs in relation to the side effect of bleeding.
However, as discussed above, it cannot necessary be assumed that these results could be extrapolated to patients who did not have "established coronary artery disease"
Kind Regards, John